Difference between revisions of "Biphenotypic sinonasal sarcoma"
Jump to navigation
Jump to search
(→IHC) |
(→IHC) |
||
| Line 32: | Line 32: | ||
*Actin +ve (27 +ve of 28 cases<ref name=pmid22301502/>). | *Actin +ve (27 +ve of 28 cases<ref name=pmid22301502/>). | ||
*Beta-catenin - nuclear +ve.<ref>http://dx.doi.org/10.1016/j.humpath.2016.04.009 | *Beta-catenin - nuclear +ve.<ref>http://dx.doi.org/10.1016/j.humpath.2016.04.009 | ||
</ref>< | </ref><ref name=pmid25488011>{{Cite journal | last1 = Powers | first1 = KA. | last2 = Han | first2 = LM. | last3 = Chiu | first3 = AG. | last4 = Aly | first4 = FZ. | title = Low-grade sinonasal sarcoma with neural and myogenic features--diagnostic challenge and pathogenic insight. | journal = Oral Surg Oral Med Oral Pathol Oral Radiol | volume = 119 | issue = 5 | pages = e265-9 | month = May | year = 2015 | doi = 10.1016/j.oooo.2014.10.007 | PMID = 25488011 }}</ref> | ||
Others:<ref name=pmid25488011/> | |||
*Desmin -ve. | |||
*AE1/AE3 -ve. | |||
*Vimentin +ve. | |||
==Molecular== | ==Molecular== | ||
Revision as of 17:50, 1 May 2016
Biphenotypic sinonasal sarcoma, abbreviated SNS,[1] is a rare bland appearing malignant tumour of the head and neck.
It is also known as low grade sinonasal sarcoma with neural and myogenic features.[2]
General
- Rare - largest series published (as of 2012) 28 patients.[3]
- Female predominant - (female:male = 3:1[3]).
Prognosis:
- No (far away) metastasis or death in a series of 28 patients.[3]
Gross
- Usually ethmoid sinus and/or nasal cavity.[3]
Microscopic
Features:
- Bland hypercellular stroma typically without many mitoses.
- Invaginating glandular epithelium.
Note:
- May have rhabdomyoblastic differentiation - case report.[4]
DDx:
IHC
Features:
- S-100 +ve - strong (28 +ve of 28 cases[3]).
- Actin +ve (27 +ve of 28 cases[3]).
- Beta-catenin - nuclear +ve.[5][6]
Others:[6]
- Desmin -ve.
- AE1/AE3 -ve.
- Vimentin +ve.
Molecular
- PAX3-MAML3 fusion - t(2;4)(q35;q31.1).[1]
See also
References
- ↑ 1.0 1.1 Wang, X.; Bledsoe, KL.; Graham, RP.; Asmann, YW.; Viswanatha, DS.; Lewis, JE.; Lewis, JT.; Chou, MM. et al. (Jul 2014). "Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma.". Nat Genet 46 (7): 666-8. doi:10.1038/ng.2989. PMID 24859338.
- ↑ Powers, KA.; Han, LM.; Chiu, AG.; Aly, FZ. (May 2015). "Low-grade sinonasal sarcoma with neural and myogenic features--diagnostic challenge and pathogenic insight.". Oral Surg Oral Med Oral Pathol Oral Radiol 119 (5): e265-9. doi:10.1016/j.oooo.2014.10.007. PMID 25488011.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Lewis, JT.; Oliveira, AM.; Nascimento, AG.; Schembri-Wismayer, D.; Moore, EA.; Olsen, KD.; Garcia, JG.; Lonzo, ML. et al. (Apr 2012). "Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases.". Am J Surg Pathol 36 (4): 517-25. doi:10.1097/PAS.0b013e3182426886. PMID 22301502.
- ↑ Huang, SC.; Ghossein, RA.; Bishop, JA.; Zhang, L.; Chen, TC.; Huang, HY.; Antonescu, CR. (Jan 2016). "Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation.". Am J Surg Pathol 40 (1): 51-9. doi:10.1097/PAS.0000000000000492. PMID 26371783.
- ↑ http://dx.doi.org/10.1016/j.humpath.2016.04.009
- ↑ 6.0 6.1 Powers, KA.; Han, LM.; Chiu, AG.; Aly, FZ. (May 2015). "Low-grade sinonasal sarcoma with neural and myogenic features--diagnostic challenge and pathogenic insight.". Oral Surg Oral Med Oral Pathol Oral Radiol 119 (5): e265-9. doi:10.1016/j.oooo.2014.10.007. PMID 25488011.